MicroPort CardioFlow Medtech Corporation(CardioFlow) ，one of the world's leading innovative medical device companies, has entered the field of structural heart disease when the field was still at an early adoption phase. Originating and headquartered in Shanghai, China, CardioFlow was listed on the Hong Kong Stock Exchange on February 2021(Stock Code: 02160.HK).

CardioFlow has a diverse product pipeline resulting from independent and collaborative research, covering structural heart devices such as transcatheter aortic, mitral and tricuspid valves and accessories，as well as left atrial appendage occludes . Leveraging its technological expertise and capacity for innovation, the company has successfully obtained approvals and launched several TAVI products globally, among which VitaFlow Liberty^® stands out as the world's only electric retrievable transcatheter aortic valve system and has been granted EU CE-MDR Mark in 2024.

Currently, the VitaFlow^® series TAVI solution along with its accessory - the Alwide^® series balloon catheter, has successfully covered over 700 core hospitals in over 20 countries and regions, treating more than 10,000 patients with aortic valve disease worldwide.